Alpha-1 Antitrypsin Deficiency Augmentation Therapy Global Market Report 2024

Description

“Alpha-1 Antitrypsin Deficiency Augmentation Therapy Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on alpha-1 antitrypsin deficiency augmentation therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for alpha-1 antitrypsin deficiency augmentation therapy? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The alpha-1 antitrypsin deficiency augmentation therapy market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Product Type: Glassia; Aralast NP; Prolastin C; Zemaira And Respreeza
2) By Route Of Administration: Oral; Injection; Inhalation
3) By End User: Hospitals; Specialty Clinics; Other End Users
Companies Mentioned: Pfizer Inc.; Sanofi S.A.; AstraZeneca plc; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Alpha-1 antitrypsin deficiency augmentation therapy is a medical intervention that involves the infusion of purified alpha-1 antitrypsin protein into individuals with deficient levels. This therapy is designed to protect the lungs from damage caused by an imbalance of protease and antiprotease enzymes, with the goal of slowing the progression of emphysema and enhancing lung function in affected patients.

The primary products used in alpha-1 antitrypsin deficiency augmentation therapy include Glassia, Aralast NP, Prolastin C, Zemaira, and Respreeza. Glassia, for instance, is a medication comprising human Alpha1-Proteinase inhibitors (Alpha1-PI) and is indicated for the treatment of lung disease (emphysema) in adults with severe alpha1-antitrypsin (Alpha1) deficiency. These therapeutic products are administered through various methods, including oral, injection, and inhalation, and are typically provided in healthcare settings such as hospitals, specialty clinics, and more.

The alpha-1 antitrypsin deficiency augmentation therapy market research report is one of a series of new reports from The Business Research Company that provides alpha-1 antitrypsin deficiency augmentation therapy market statistics, including alpha-1 antitrypsin deficiency augmentation therapy industry global market size, regional shares, competitors with an alpha-1 antitrypsin deficiency augmentation therapy market share, detailed alpha-1 antitrypsin deficiency augmentation therapy market segments, market trends and opportunities and any further data you may need to thrive in the alpha-1 antitrypsin deficiency augmentation therapy industry. This alpha-1 antitrypsin deficiency augmentation therapy market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The alpha-1 antitrypsin deficiency augmentation therapy market size has grown strongly in recent years. It will grow from $1.58 billion in 2023 to $1.69 billion in 2024 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to improved diagnosis, awareness campaigns, clinical research, aging population.

The alpha-1 antitrypsin deficiency augmentation therapy market size is expected to see strong growth in the next few years. It will grow to $2.26 billion in 2028 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to telehealth and remote monitoring, precision medicine, gene therapy developments. Major trends in the forecast period include long-term safety and efficacy data, patient-centered care models, tele-rehabilitation programs, personalized dosing regimens.

The alpha-1 antitrypsin deficiency augmentation therapy market is experiencing growth due to the rising prevalence of respiratory diseases. Respiratory diseases encompass a range of conditions affecting the lungs and the respiratory system, leading to breathing difficulties and compromised lung function. Alpha-1 antitrypsin deficiency augmentation therapy plays a crucial role in addressing respiratory diseases by supplementing the deficient protein in individuals with alpha-1 antitrypsin deficiency. This therapy restores the balance of protease-antiprotease activity in the lungs, shielding lung tissue from damage caused by excessive neutrophil elastase activity and reducing inflammation. Notably, according to data from the Centers for Disease Control and Prevention as of March 2023, there were 8,300 reported cases of tuberculosis (TB) in the United States in 2022, marking an increase from the 7,874 cases recorded in 2021. As such, the growing prevalence of respiratory diseases is a key driver for the alpha-1 antitrypsin deficiency augmentation therapy market.

Anticipated growth in the alpha-1 antitrypsin deficiency augmentation therapy market is linked to the escalation in the number of clinical trials. Clinical trials represent essential biomedical or behavioral research studies conducted with human participants to address specific questions about interventions, encompassing new treatments and known interventions necessitating further evaluation and comparison. These trials hold immense significance in the development and approval of novel therapies and medications for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). The surge in clinical trials signifies a heightened interest in the development of fresh AATD therapies, potentially leading to the introduction of more effective treatments in the market. For instance, a report by Xtalks as of May 2023 reveals that there were 452,604 clinical studies registered on ClinicalTrials.gov. This number represents a notable increase from the over 365,000 registered trials documented in early 2021. Consequently, the upsurge in clinical trials is a driving force behind the growth of the alpha-1 antitrypsin deficiency augmentation therapy market.

The future growth of the alpha-1 antitrypsin deficiency augmentation therapy market faces potential limitations due to the availability of only a limited number of approved medications. This constraint can restrict the treatment options accessible to both patients and healthcare providers. Currently, augmentation therapy with purified intravenous alpha-1 antitrypsin is the sole approved treatment for Alpha-1 Antitrypsin Deficiency (AATD). For example, data from the COPD Foundation, a nonprofit organization based in the United States, reveals that annual medical expenses for individuals utilizing augmentation therapy for AATD amount to $127,537, while non-users incur expenses of $15,874. Approximately 75.3% of patients opt for augmentation therapy. Consequently, the limited availability of approved medications acts as a hindrance to the growth of the alpha-1 antitrypsin deficiency augmentation therapy market.

Prominent companies operating in the acute respiratory distress syndrome (ARDS) market are placing their focus on the development of innovative therapies, particularly those rooted in recombinant technology-based drug development, to maintain their competitive position in the market. Recombinant DNA technology is utilized to create therapeutic pharmaceuticals via recombinant technology-based drug development. This approach involves modifying the DNA of living organisms to synthesize specific proteins. As an illustration, in March 2022, Inhibrx Inc., a biotechnology company based in the United States, announced the U.S. Food and Drug Administration's (FDA) grant of orphan drug designation to INBRX-101 for the treatment of alpha-1 antitrypsin deficiency (AATD). INBRX-101 represents a recombinant human AAT-Fc fusion protein designed for potential once-monthly dosing to safely achieve and maintain AAT levels comparable to those found in healthy individuals.

In January 2023, GlaxoSmithKline PLC, a United Kingdom-based pharmaceutical and biotechnology company, made a significant investment by acquiring an 11% stake in Wave Life Sciences Ltd. for $50 million. This strategic move aims to leverage GSK's expertise in human genetics, global development, and commercial capabilities in collaboration with Wave's proprietary discovery and drug development platform, PRISMTM. The objective is to expedite the progress of oligonucleotide therapeutics for genetically determined diseases, including the treatment of Alpha-1 Antitrypsin Deficiency (AATD). Wave Life Sciences Ltd. is a clinical-stage RNA medicine company based in the United States, specializing in the development of drugs for AATD and other conditions.

Major players in the alpha-1 antitrypsin deficiency augmentation therapy market are Pfizer Inc., Sanofi S.A., AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Amgen Inc., Baxter International Inc., CSL Limited, Biogen Inc., Vertex Pharmaceuticals Incorporated, Grifols S.A., BioMarin Pharmaceutical Inc., LFB Group, Octapharma AG, Arrowhead Pharmaceuticals Inc., Kamada Ltd., Krystal Biotech Inc., Intellia Therapeutics Inc., Mereo BioPharma Group PLC, Protalix BioTherapeutics Inc., Centessa Pharmaceuticals Limited, Inhibrx Inc., Liminal BioSciences Inc., Applied Genetic Technologies Corporation, Abeona Therapeutics Inc.

North America was the largest region in the alpha-1 antitrypsin deficiency augmentation therapy market in 2023. The regions covered in alpha-1 antitrypsin deficiency augmentation therapy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the alpha-1 antitrypsin deficiency augmentation therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The alpha-1 antitrypsin deficiency augmentation therapy market consists of sales of Fazirsiran and RNA interference (RNAi) therapy. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Product Code: r12352

1. Executive Summary

2. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Characteristics

3. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Trends And Strategies

4. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size and Growth

5.1. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Segmentation

6.1. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Glassia
Aralast NP
Prolastin C
Zemaira And Respreeza
6.2. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Oral
Injection
Inhalation
6.3. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospitals
Specialty Clinics
Other End Users

7. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Regional And Country Analysis

7.1. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

8.1. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

9.1. China Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Overview
9.2. China Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

10.1. India Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

11.1. Japan Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Overview
11.2. Japan Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

12.1. Australia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

13.1. Indonesia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

14.1. South Korea Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Overview
14.2. South Korea Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

15.1. Western Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Overview
15.2. Western Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

16.1. UK Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

17.1. Germany Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

18.1. France Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

19.1. Italy Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

20.1. Spain Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

21.1. Eastern Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Overview
21.2. Eastern Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

22.1. Russia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

23.1. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Overview
23.2. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

24.1. USA Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Overview
24.2. USA Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

25.1. Canada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Overview
25.2. Canada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

26.1. South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Overview
26.2. South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

27.1. Brazil Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

28.1. Middle East Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Overview
28.2. Middle East Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

29.1. Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Overview
29.2. Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Competitive Landscape And Company Profiles

30.1. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Competitive Landscape
30.2. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Company Profiles
- 30.2.1. Pfizer Inc.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Sanofi S.A.
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. AstraZeneca plc
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. GlaxoSmithKline plc
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Takeda Pharmaceutical Company Limited
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Other Major And Innovative Companies

31.1. Amgen Inc.
31.2. Baxter International Inc.
31.3. CSL Limited
31.4. Biogen Inc.
31.5. Vertex Pharmaceuticals Incorporated
31.6. Grifols S.A.
31.7. BioMarin Pharmaceutical Inc.
31.8. LFB Group
31.9. Octapharma AG
31.10. Arrowhead Pharmaceuticals Inc.
31.11. Kamada Ltd.
31.12. Krystal Biotech Inc.
31.13. Intellia Therapeutics Inc.
31.14. Mereo BioPharma Group PLC
31.15. Protalix BioTherapeutics Inc.

32. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Competitive Benchmarking

33. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market

35. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Future Outlook and Potential Analysis

35.1 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market In 2028 - Countries Offering Most New Opportunities
35.2 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market In 2028 - Segments Offering Most New Opportunities
35.3 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer